🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Canada / NCT04893863
Recruiting Phase 1/2

A Study of Plurogel® Compared to Standard Topical Dressing in Burn Injuries

NCT04893863 · tracked via the Priya Life Science Canada tracker
Phase
Phase 1/2
Started
2021-10-01
Last updated
2026-05-14

Condition(s) studied

Burns

Investigational drug(s) / intervention(s)

Standard dressing →PluroGel →

Standard dressing: Topical antibiotic ointment (Polysporin™ or formulary equivalent) and non-adherent petrolatum fine-meshed gauze (ADAPTIC™) applied every Monday, Wednesday and Friday (or equivalent).

PluroGel: A 0.5 cm layer of PluroGel® followed by the above standard dressing. In addition, this will be covered with moistened gauze, kept moist twice daily. (The additional factors are the use of PluroGel® and moistened gauze. Standard dressing will continue to be used.)

Study summary

Burn injuries can result in long term physical and mental sequelae, not only from the scarring but also the painful dressings. The standard of care today remains use of antibiotic topical dressings while awaiting demarcation of the burn depth, with surgical excision and grafting for deep partial thickness and full thickness areas. Demarcation can be appreciated on admission for full thickness burns but is often a prolonged process that can last weeks. The clinical evaluation of the depth of the burn is a complex decision that often is made more challenging by the presence of the proteinaceous pseudoeschar and the coagulated dermis itself. Surgical debridement is relatively 'coarse' and by its very nature requires removal of a thin layer of viable tissue to reach the level that is vascularized enough to support a skin graft. There has been growing interest in the use of adjuncts to reduce the amount tissue debrided and potentially reduce the need for surgery itself. Operatively, there have been some reports that use of hydro-dissection devices (Versajet™) may allow a more controlled debridement, resulting in less viable tissue being sacrificed. There is also a growing experience with enzymatic debridement, especially with Bromolein, derived from Pineapple (NexoBrid®). Neither of these have been shown to definitively improve care in randomized controlled trials, (RCTs) and there is suggestion that in some settings may actually cause harm.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Persons with bilateral limb partial thickness burn injuries of similar depth requiring admission Exclusion Criteria: * Total body surface area (TBSA) of burn \>30%. * Burn depth full thickness or deeper on initial assessment. * Prior excision at another healthcare centre. * Patients with pre-existing malnutrition * Electrical, chemical or other unusual burn etiologies

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
University of Manitoba Winnipeg Manitoba Recruiting

More University of Manitoba trials in Canada

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04893863 on ClinicalTrials.gov ↗ ← All trials in Canada